ClinicalTrials.gg
TerminatedNCT04723186Updated May 27, 2026Results posted

MT1002 Phase II Study in ACS Patients With PCI

A Phase 2 interventional study of MT1002 for Injection in Acute Coronary Syndrome, sponsored by Shaanxi Micot Pharmaceutical Technology Co., Ltd.. Terminated at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
The study was decided to be terminated due to commercial considerations,(not the safety issues of the product).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 265 studies in Acute Coronary Syndrome with a site in United States — 14 open to participants now, 21 under way, 2 of them phase 3. Acute Coronary Syndrome · United States.

Enrollment
170th of 186
6 · median 150
Started
2020
with 8 others
Phase 2
29 of 265
2 open now
Registered
228th of 265
by date

Among the 265 studies in Acute Coronary Syndrome with a site in United States, this one is the 170th largest by enrollment of the 186 interventional ones that give a count, is one of 9 that started in 2020, is one of 29 in phase 2, and was the 228th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

14 of the 265 studies in Acute Coronary Syndrome with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Acute Coronary Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, sequential-dose escalation/de-escalation trial testing 3 dose levels of MT1002 in patients undergoing PCI due to ACS with NSTEMI. Three doses of MT1002 will be sequentially tested in cohorts of 6 patients each to achieve target ACT.

Read the detailed description

MT1002 is a novel 32-amino acid synthetic peptide aimed to combine molecular functions of both a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa receptor antagonist, indicated for use as an antithrombotic and anticoagulant in patients with ACS and in patients undergoing PCI. This study is to investigate the safety, tolerability, and efficacy of MT1002 in patients undergoing PCI due to ACS with NSTEMI.

This study is a single dose, sequential-dose escalation study in patients undergoing PCI due to ACS with NSTEMI. The first 2 doses were considered safe and well tolerated in the Phase 1 healthy subject study. The third dose to be given will be determined based on the safety and efficacy results from the first 2 doses. Dose escalation/de-escalation and stopping rules have been put in place to ensure the safety of the patients in this study.

The patients will receive a single MT1002 close to the initiation of PCI (Day 1) followed by 4 hours of IV infusion and follow-up at Day 2, Day 14, and Day 30.

03

Conditions studied

  • Acute Coronary Syndrome

Keywords

  • ACS, PCI
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females ≥ 18 to 85 years of age.
  2. Diagnosed with NSTEMI.
  3. Patients who will undergo PCI during the index hospitalization for an NSTEMI.
  4. Ability to understand and willing to give written .
  5. Women of must have a negative pregnancy test or be for at least 1 year before enrollment or be permanently sterilized since ≥6 weeks. Females of childbearing potential and males with partners of childbearing potential must be using effective .

Exclusion criteria

Exclusion Criteria:

  1. .Cardiogenic shock or prolonged cardiopulmonary resuscitation (CPR).
  2. Active bleeding, bleeding diathesis, coagulopathy.
  3. Any history of intracranial bleeding or structural abnormalities.
  4. Prior , prior stroke within 6 months.
  5. Index MI is STEMI or new left bundle branch block.
  6. The following planned procedures within 30 days after enrollment: staged PCI, CABG, valve surgery, or additional invasive procedures.
  7. Pre-existing atrial fibrillation or prolonged (470ms in men, 480ms in women).
  8. Anticipated requirement for oral anticoagulants before Day 30.
  9. CRUSADE bleeding risk score >40.
  10. Suspected aortic dissection.
  11. History of gastrointestinal or genitourinary bleeding within the previous 3 months.
  12. Refusal to receive blood transfusion if needed during the study.
  13. Major surgery in the last month.
  14. History of heparin-induced thrombocytopenia and bleeding diathesis.
  15. Severe uncontrolled hypertension.
  16. Prior (within 30 days prior to enrollment) or planned administration of thrombolytics, glycoprotein IIb/IIIa inhibitors, bivalirudin, or fondaparinux for the index MI.
  17. Known relevant hematological deviations: (male) \< 11 g/dL, hemoglobin (female) \< 10 g/dL, hematocrit \< 35%, count \< 100,000 cells/µL.
  18. Use of Coumadin derivatives and/or Factor Xa inhibitor drugs within the last 7 days.
  19. Chronic therapy with non-steroidal anti-inflammatory drugs (NSAIDs; except aspirin) , cyclooxygenase (COX)-2 inhibitors within 1 month before screening.
  20. Known or other comorbid conditions with \< 1 year.
  21. Known severe liver disease (i.e., [AST], alanine aminotransferase [ALT] > 3 × ).
  22. Known positive serology for \& C, screen.
  23. Known chronic kidney disease with estimated (eGFR) \<30 mL/min and/or dialysis.
  24. Known allergy or intolerance to aspirin, clopidogrel, ticagrelor, prasugrel, bivalirudin, unfractionated heparin, P2Y12 antagonists, or contrast.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Monotherapy of MT1002, 3 doses via intravenous (IV) + infusion

    Three doses of MT1002 (IV loading + continuous IV infusion) will be sequentially tested. The first dose level is 0.90 mg/kg initial loading dose (bolus intravenous injection) + 1.8 mg/kg/h (infusion) for 4 hours. The second dose level will be based on the results from the first cohort (If the dose is escalated, then the second dose level is 1.2 mg/kg initial loading dose (bolus intravenous injection) + 2.3 mg/kg/h (infusion) for 4 hours; if the dose is de-escalated, then the second dose level is 0.6 mg/kg initial loading dose (bolus intravenous injection) + 1.2 mg/kg/h (infusion) for 4 hours). The third dose will be determined based on the results from the first 2 cohorts.

    Drug: MT1002 for Injection

Interventions

  • DrugMT1002Studies of MT1002MT1002 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    MT1002 will be initiated as close to the start of PCI as possible. MT1002 should be initiated during diagnostics angiography when indication for PCI is confirmed, provided the PCI is indicated right after the coronary angiography. PCI can start after MT1002 initiation as soon as ACT is confirmed to be ≥ 200 sec or within 30 min after MT1002 starts, whichever occurs first. MT1002 will be administered by an intravenous injection of 0.90 mg/kg, 1.2 mg/kg, or 0.6 mg/kg (depending on the dose selected for the cohort) prior to the PCI procedure, immediately followed by an IV infusion of 1.8 mg/kg/hour, 2.3 mg/kg/hour, or 1.2 mg/kg/hour (depending on the dose selected for the cohort) until completion of the procedure. At completion of PCI, subjects will be continued on IV MT1002 for 4 hours from infusion start.

06

What researchers measure

Primary outcomes

  1. Co-Primary Composite Endpoint

    Composite of: 1. achievement of target ACT (200-300 sec) on MT1002 without switching to standard of care from the start of coronary angiography through the end of the PCI procedure (up to 4 hours of continuous infusion), and successful PCI; 2. occurrence of BARC Type 3-5 major bleeding events from initiation of study drug through 30 days post-PCI.

    Time frame: During PCI on day 1, and up to 30 days follow up

Secondary outcomes

  1. Major Adverse Cardiovascular Events (MACE)

    MACE is defined as nonfatal MI, unplanned revascularization (PCI or CABG) of the ischemic target vessel including intraprocedural stent thrombosis, re-hospitalization for a CV-related condition, nonfatal stroke, CV death, and all-cause mortality.

    Time frame: 30 days

07

Results

Posted May 27, 2026

Participant flow

12 patients were screended, 6 patients were enrolled into the first dose group and dosed of MT1002 0.90mg/kg bonus+1.8mg/kg/h×4h infusion.

Participant flow — Overall Study
MilestoneMT1002 0.90mg/kg Bonus+1.8mg/kg/h×4h Infusion
Started6
Completed6
Not completed0

Outcome measures

PrimaryCo-Primary Composite Endpoint

Composite of: 1. achievement of target ACT (200-300 sec) on MT1002 without switching to standard of care from the start of coronary angiography through the end of the PCI procedure (up to 4 hours of continuous infusion), and successful PCI; 2. occurrence of BARC Type 3-5 major bleeding events from initiation of study drug through 30 days post-PCI.

Time frame:
During PCI on day 1, and up to 30 days follow up
Reported as:
Count of participants · Participants
Co-Primary Composite Endpoint
ParticipantsMT1002 0.90mg/kg Bonus+1.8mg/kg/h×4h Infusion
The number of patients with target ACT (200 -300 seconds [sec]) achieved on MT1002 prior/during PCI.6
Bleeding events major (Bleeding Academic Research Consortium [BARC] Type 3-5)0
SecondaryMajor Adverse Cardiovascular Events (MACE)

MACE is defined as nonfatal MI, unplanned revascularization (PCI or CABG) of the ischemic target vessel including intraprocedural stent thrombosis, re-hospitalization for a CV-related condition, nonfatal stroke, CV death, and all-cause mortality.

Time frame:
30 days
Reported as:
Count of participants · Participants
Major Adverse Cardiovascular Events (MACE)
ParticipantsMonotherapy of MT1002, 3 Doses Via Intravenous (IV) + Infusion
Major Adverse Cardiovascular Events (MACE)0

Adverse events

Collected over From enrollment until end of follow-up, which is 30 days after PCI.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MT1002 0.90mg/kg Bonus+1.8mg/kg/h×4h Infusion0/6 (0%)0/6 (0%)2/6 (33.3%)
Most frequent other events
Most frequent other events
EventMT1002 0.90mg/kg Bonus+1.8mg/kg/h×4h Infusion
HypokalaemiaMetabolism and nutrition disorders1/6
Blood creatinine increasedInvestigations1/6
Troponin increasedInvestigations1/6
NauseaGastrointestinal disorders1/6
Chest painRespiratory, thoracic and mediastinal disorders1/6
HyperlipidaemiaMetabolism and nutrition disorders1/6
Blood creatine phosphokinase MB increasedInvestigations1/6
HaematomaVascular disorders1/6
EpistaxisRespiratory, thoracic and mediastinal disorders1/6
Vision blurredEye disorders1/6

Baseline characteristics

Age, Continuous
Age, Continuous(Years)MT1002 0.90mg/kg Bonus+1.8mg/kg/h×4h Infusion
Mean65.7 (51 to 72)
Sex: Female, Male
Sex: Female, Male(Participants)MT1002 0.90mg/kg Bonus+1.8mg/kg/h×4h Infusion
Female1
Male5
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MT1002 0.90mg/kg Bonus+1.8mg/kg/h×4h Infusion
Hispanic or Latino0
Not Hispanic or Latino6
Unknown or Not Reported0
CRUSADE Bleeding Risk Score
CRUSADE Bleeding Risk Score(Participants)MT1002 0.90mg/kg Bonus+1.8mg/kg/h×4h Infusion
CRUSADE Bleeding Risk Score ≤204
CRUSADE Bleeding Risk Score from 31-402
08

Study locations

1 site
  • IU Health - BMH
    Muncie, Indiana 47303, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Aug 2023, 32 months.

Results were first posted in May 2026, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2021
First posted
Jan 25, 2021
StartActual
Dec 2, 2020
Primary completionActual
Aug 31, 2023
CompletionActual
Aug 31, 2023
Results first posted
May 27, 2026
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04723186
Lead sponsor
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Jan 25, 2021
Start date
Dec 2, 2020
Primary completion
Aug 31, 2023
Completion
Aug 31, 2023
Results posted
May 27, 2026
Last update
May 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MT1002

Start the discussion